CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.

Tumour suppressor gene (TSG) silencing through promoter hypermethylation plays an important role in cancer initiation. The aim of this study was to assess the extent of methylation of APC gene promoter in 91 sporadic and 44 familial cases of Tunisian patients with breast cancer (BC) in. The frequency of APC promoter methylation is somewhat similar for sporadic and familial breast cancer cases, (52.1%, and 54.5% respectively). For sporadic breast cancer patients, there was a significant correlation of APC promoter hypermethylation with TNM stage (p = 0.024) and 3-year survival (p = 0.025). Regarding the hormonal status (HR), we found significant association between negativity to PR and unmethylated APC (p= 0.005) while ER and Her2/neu are not correlated. Moreover, unmethylated APC promoter is more frequent in tumours expressing at least one out the 3 proteins compared to triple negative cases (p= 0.053). On the other hand, aberrant methylation of APC was associated with tumour size (p = 0.036), lymph node (p = 0.028), distant metastasis (p = 0.031), and 3-year survival (p = 0.046) in the group of patients with familial breast cancer. Moreover, patients with sporadic breast cancer displaying the unmethylated profile have a significant prolonged overall survival compared to those with the methylated pattern of APC promoter (p log rank = 0.008). Epigenetic change at the CpG islands in the APC promoter was associated with the silence of its transcript and the loss of protein expression suggesting that this event is the main mechanism regulating the APC expression in breast cancer. In conclusion, our data showed that the loss of APC through aberrant methylation is associated with the aggressive behavior of both sporadic and familial breast cancer in Tunisian patients.

[1]  A. Neugut,et al.  Gene promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[2]  J. Herman,et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. , 2000, Cancer research.

[3]  T. Motoyama,et al.  Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers , 2001, British Journal of Cancer.

[4]  A. Khabir,et al.  Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma , 2009, Journal of biomedicine & biotechnology.

[5]  R. Brentani,et al.  Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  S. Mirza,et al.  Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. , 2008, Life sciences.

[7]  A. Neugut,et al.  BRCA1 promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[8]  J. Minna,et al.  Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  E. Robertson,et al.  Epigenetic Regulation of Tumor Suppressors by Helicobacter pylori Enhances EBV-Induced Proliferation of Gastric Epithelial Cells , 2018, mBio.

[10]  A. Wyllie,et al.  Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. , 1993, British Journal of Cancer.

[11]  A. Cheung,et al.  Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. , 2004, Gynecologic oncology.

[12]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[13]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[14]  R Kemler,et al.  beta-catenin is a target for the ubiquitin-proteasome pathway. , 1997, The EMBO journal.

[15]  R. Moon,et al.  The APC tumor suppressor protein in development and cancer. , 1997, Trends in genetics : TIG.

[16]  F. C. Lucibello,et al.  Localization of the gene for familial adenomatous polyposis on chromosome 5 , 1987, Nature.

[17]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[18]  M. Taketo,et al.  Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene , 2007, Journal of Cell Science.

[19]  S Ichii,et al.  Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. , 1992, Human molecular genetics.

[20]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[21]  M. Swellam,et al.  Aberrant methylation of APC and RARβ2 genes in breast cancer patients , 2015, IUBMB life.

[22]  S. Nishizuka,et al.  Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia , 2000, Oncogene.

[23]  R. Parsons,et al.  APC truncation and increased beta-catenin levels in a human breast cancer cell line. , 2000, Carcinogenesis.

[24]  K. Amara,et al.  Evidence for a role of the Simian Virus 40 in human breast carcinomas , 2008, Breast Cancer Research and Treatment.

[25]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[26]  P. Polakis,et al.  Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[28]  J Herman,et al.  Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[30]  Å. Borg,et al.  Involvement of adenomatous polyposis coli (APC)/β-catenin signalling in human breast cancer , 2000 .

[31]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.

[32]  Paul Cairns,et al.  Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients , 2004, Clinical Cancer Research.

[33]  J. McPherson,et al.  Identification of deletion mutations and three new genes at the familial polyposis locus , 1991, Cell.

[34]  J. Jónasson,et al.  Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer , 2006, Breast Cancer Research.

[35]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[36]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[37]  W. Ballhausen,et al.  Identification of an alternative 5′ untranslated region of the adenomatous polyposis coli gene , 1993, Human Genetics.

[38]  B. X. Trinh,et al.  Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype , 2008, British Journal of Cancer.

[39]  M. Tada,et al.  Somatic mutations of the APC gene in primary breast cancers. , 2000, The American journal of pathology.

[40]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[41]  R. Parsons,et al.  APC truncation and increased β-catenin levels in a human breast cancer cell line , 2000 .

[42]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[43]  H. Clevers.  Wnt/beta-catenin signaling in development and disease. , 2006, Cell.

[44]  Lam,et al.  Reduced expression of APC and DCC gene protein in breast cancer , 1999, Histopathology.